NeoGenomics vs Veracyte
NEO and VCYT side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NEO and VCYT compare
NeoGenomics and Veracyte are about the same size, with market caps of $2.0B and $1.9B.
Veracyte grew revenue faster over the last twelve months (17.3% versus 11.1% for NeoGenomics).
Veracyte keeps more of each dollar of sales as profit, with a net margin of 20.4% compared with −4.1% at NeoGenomics.
Veracyte scores higher on the StockData Score (16 against 11 for NeoGenomics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NEO | VCYT |
|---|---|---|
| Size and price | ||
| Market cap | $2.0B | $1.9B |
| Share price | $15.41 | $24.01 |
| Change, 1 year | 53.9% | −39.8% |
| Change, 5 years | −58.0% | −42.2% |
| Beta (5Y) | 0.84 | 1.93 |
| Employees | 2,500 | 755 |
| StockData Score | ||
| Total score | 11 | 16 (better) |
| Valuation score | 3 | 4 (better) |
| Growth score | 4 (better) | 3 |
| Performance score | 3 | 3 |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 17.1× |
| P/S | 2.5× (better) | 3.4× |
| P/B | 2.5× | 1.4× (better) |
| EV/EBITDA | – | 12.9× |
| P/FCF | – | 11.6× |
| FCF yield | −1.4% | 8.6% (better) |
| Fair value | $19.92 | $36.49 |
| Margin of safety | 22.6% | 34.2% (better) |
| Growth | ||
| Revenue growth (TTM) | 11.1% | 17.3% (better) |
| Revenue growth, 5Y average | 10.4% | 34.5% (better) |
| Net income growth (TTM) | – | 335% |
| EPS growth (TTM) | – | 324% |
| Profitability | ||
| Gross margin | 44.8% | 71.7% (better) |
| Operating margin | −6.3% | 18.8% (better) |
| Net margin | −4.1% | 20.4% (better) |
| FCF margin | −3.6% | 29.5% (better) |
| Return on equity | −3.9% | 8.8% (better) |
| Return on invested capital | −4.6% | 10.0% (better) |
| Financial health | ||
| Debt / equity | 0.47 (better) | 0.00 |
| Interest coverage | −15.2× | – |
| Current ratio | 3.53 | 9.16 (better) |
| Altman Z-score | 2.32 | 12.54 (better) |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | −0.02% | – |
| Shareholder yield | −0.02% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 112% | 111% |
| Held by insiders | 1.5% | 1.7% |
| Insider net buying, 12 months | −$717K (better) | −$18.6M |
| Short interest, % of float | 10.3% | 12.1% |
Go deeper
- NEO stock overview
- NEO income statement
- NEO valuation and score
- VCYT stock overview
- VCYT income statement
- VCYT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.